Drug Profile
Recombinant factor VIIa - rEVO Biologics/LFB Biotechnologies
Alternative Names: CEVENFACTA; COAGULATION FACTOR VIIA RECOMBINANT - rEVO Biologics/LFB; EPTACOG BETA ACTIVATED; LR 769; rhFVIIa; SEVENFACT; SevenfactLatest Information Update: 19 Jan 2023
Price :
$50
*
At a glance
- Originator GTC Biotherapeutics; LFB Biotechnologies
- Developer HEMA Biologics; LFB Biotechnologies; rEVO Biologics
- Class Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A; Haemophilia B
Most Recent Events
- 10 Dec 2022 Updated efficacy data from the phase III PERSEPT 1 trial in Haemophilia A and B presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 10 Dec 2022 Updated efficacy data from a phase III trial in Haemophilia A and B presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 25 Jul 2022 9363646: incorporated QC feedback